A5051739385- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- COVID-19 and healthcare impacts
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Hemoglobinopathies and Related Disorders
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- COVID-19 Clinical Research Studies
- Acute Lymphoblastic Leukemia research
- Gastrointestinal Tumor Research and Treatment
- Hematopoietic Stem Cell Transplantation
- Retinoids in leukemia and cellular processes
- Inflammatory Biomarkers in Disease Prognosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- COVID-19 and Mental Health
- Gastric Cancer Management and Outcomes
- Sepsis Diagnosis and Treatment
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- T-cell and B-cell Immunology
Union Hospital
2022-2023
Huazhong University of Science and Technology
2012-2023
Wuhan Union Hospital
2020
9009 Background: Imatinib mesylate benefits over 80% of patients with metastatic GIST, but whether it is tolerable and effective as an adjuvant therapy after complete resection primary GIST unknown. Methods: Patients who had undergone gross a that expressed KIT were at high risk (tumor size ≥10 cm, tumor rupture, or <5 peritoneal metastases) for recurrence accrued from 48 institutions. Prospective central pathologic confirmation was inclusion criterion the diagnosis could not be confirmed in...
CD44v6 chimeric antigen receptor T (CD44v6 CAR-T) cells demonstrate strong anti-tumor ability and safety in acute myeloid leukemia (AML). However, the expression of on leads to transient fratricide exhaustion CAR-T cells, which affect application CAR-T. The function AML are associated with DNA methylation. Hypomethylating agents (HAMs) decitabine (Dec) azacitidine (Aza) have been widely used treat AML. Therefore, there may be synergy between HAMs treatment AML.CD44v6 pretreated Dec or Aza...
Abstract Although tyrosine kinase inhibitors (TKIs) improve the prognosis of chronic myeloid leukemia (CML) patients, resistance to TKIs and residual stem cells (LSCs) inevitably become bottleneck cure. Therefore, we need explore novel treatment strategies based on conventional strategies. Our previous study found that CML cell senescence may be one main factors achieve clinical cure CML. Studies have shown lipid metabolism plays a key role in cellular senescence. Here, long-chain acyl-CoA...
Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte are reported to reflect the inflammation immune status in critically ill patients, but their role severe trauma patients with persistent critical illness remains be elucidated.We aimed evaluate relationship of neutrophil-to-lymphocyte patients.In a single-center retrospective cohort study, was defined as intensive care unit length stay more than 10 days. Monocyte-to-lymphocyte were computed individually categorized into 3 tertiles....
Background: Since late December 2019, the outbreak of novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic China and more than 100 countries regions world. There is no report about prevalence COVID-19 CML patients untill now. We aimed to describe clinical course, outcomes with patients. Methods: In this multi-center survey, cross-sectional observational study, data each center were collected. Simultaneously, an online survey was conducted for information under...
Objective: To compare the clinical efficacy and safety of nilotinib imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia phase(CML-CP). Methods: Until December 31st 2016, 18 using 83 were recruited our study. The two groups evaluated. Results: A total 101 CML-CP included receiving imatinib. optimal response rates at 3, 6, 12 months group 88.9% (16/18) vs 57.3% (47/82) (P=0.012), 82.4% (14/17) 55.7% (44/79) (P=0.041), 9/12 63.9% (39/61) (P=0.460), 6/9 68.9%...
Background To curb the spread of coronavirus disease 2019 (COVID-19) epidemic, Chinese government shut down Wuhan city from January 23rd to April 8th, 2020. The COVID-19 epidemic not only leads widespread illness but also affects diagnosis and treatment hematopoietic stem-cell transplant (HSCT) recipients. Objective investigate medical-seeking pattern daily behavior changes in Hubei Province during lockdown. Methods We conducted a multicenter, cross-sectional, web-based investigation among...